Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call indicates positive sentiment with a focus on EBITDA growth, synergy realization, and operational efficiency. Product development highlights innovation and premium applications, particularly in South America. Despite some concerns in Europe, demand signals in North America are positive. The company targets significant debt reduction and free cash flow, with strong margins in innovative products. The Q&A section reinforces positive sentiment with stable competitive behavior and growth in adult incontinence. Overall, the outlook and strategic initiatives suggest a positive impact on stock price.
Sales $792 million, with strength across consumer solutions categories offset by weaker performance in Latin America and broad-based market softness in Europe.
Adjusted EBITDA $93 million, flat year-over-year on a constant currency basis. Contributions from synergies and cost reduction initiatives offset the impact of softer demand in Europe and South America.
Americas Division Organic Volume Growth 2% growth, driven by strong demand in wipes and adult end markets. Decline in Adjusted EBITDA by $3 million due to volume and product mix pressures in South America.
Rest of World Division Adjusted EBITDA Increased by 9% to $35 million, reflecting disciplined cost management and synergy realization despite general market softness in Europe.
Free Cash Flow $97 million over the last 4 quarters, representing an 18% free cash flow yield based on market capitalization at the end of the quarter.
Available Liquidity Approximately $550 million at the end of the quarter.
Debt Repayment $27 million repaid during the quarter, with an expectation to repay approximately $100 million over the fiscal year.
Barrier protection innovation: Launched a breakthrough in healthcare applications that eliminates the need for PFAS chemicals while meeting performance requirements.
Advanced materials solution: Developed a product that extends battery life and accelerates charging times, potentially eligible for a government grant.
Kamisoft platform: Improved softness while maintaining strength; launched in North America and expanded globally, with $15 million in sales last year and mid-single-digit growth expected in 2026.
Premium disinfectant wipes: Strong growth in Americas due to elevated flu season and dynamic supply chain capabilities.
Geca Tape: Growth in high-voltage cable applications and renewable energy projects.
North America: Organic volume growth offsetting South America declines; targeted investments to enable growth in oversold platforms.
South America: Stabilizing markets with supply chain alignment; challenges from competitive imports.
Europe: Growth in infrastructure investments for utilities and data cables; operational improvements to meet demand.
Asia: Sustainability infrastructure investments driving consumer solutions growth.
Project CORE: Positioned to realize earnings benefits through global footprint optimization and cost structure alignment.
Operational excellence: Focus on efficiency and targeted investments in North America to enable growth.
Cost management: Disciplined pricing, portfolio management, and cost containment to offset market softness.
Global cost structure: Strengthening efficiency, scale, and competitiveness to maintain market leadership.
Product leadership: Fostering innovation and aligning market insights with technical excellence to create differentiated solutions.
Commercial excellence: Maximizing portfolio impact through disciplined execution and stronger customer engagement.
Consumer Spending Concerns: Despite consumer spending concerns related to inflation, the company noted resiliency in demand for essential products. However, inflationary pressures could still pose a risk to consumer behavior and overall demand.
Competitive Import Pressure in South America: The company faced year-over-year volume declines in South America due to competitive import pressure from Asia. This has led to inquiries about antidumping measures, indicating ongoing challenges in this region.
Market Softness in Europe: Broad-based market softness in Europe has negatively impacted revenues, despite some resilience in earnings.
Raw Material Cost Pass-Through: Contractual pass-through of lower raw material costs reduced revenues, particularly in South America, although it did not materially affect profitability.
Operational Challenges in South America: Volume and product mix pressures in South America have led to a decline in adjusted EBITDA for the Americas division. The company is implementing targeted initiatives to address these issues.
Economic Uncertainty: Dynamic macroeconomic conditions, including inflation and market volatility, present ongoing risks to the company's operations and financial performance.
Supply Chain Alignment: While supply chain alignment in South America is stabilizing, it remains a critical area of focus to ensure operational efficiency and customer satisfaction.
Debt and Leverage: The company is focused on deleveraging and repaid $27 million of debt during the quarter. However, maintaining financial flexibility while reducing leverage remains a challenge.
2026 adjusted EBITDA guidance: Reinforces 9% growth with synergy realization and Project CORE transformation programs tracking as planned.
Earnings stability in South America: Expected in the coming quarters as the company laps the prior year comparison in the third quarter.
Sustainability infrastructure investments: Ongoing in Europe and Asia to strengthen consumer solutions and manage energy efficiency through increased productivity.
Operational progress in North America: Targeted investments and operational excellence to enable growth opportunities in oversold platforms.
Innovation impact: Positive impact on business mix in 2026 and beyond, including transformational breakthroughs in healthcare applications and advanced materials solutions for battery life and charging times.
Kamisoft platform growth: Mid-single-digit growth expected in 2026, with $15 million in sales last year.
European infrastructure growth: Enabled by strong position in essential utility investments and maintenance projects.
Project CORE initiatives: Focused on enhancing efficiency and optimizing the regional footprint to support margin recovery in the Americas.
Capital allocation priorities: Strengthening the balance sheet with a targeted leverage ratio of 3x and repaying approximately $100 million of outstanding debt over the fiscal year.
Free Cash Flow: Free cash flow over the last 4 quarters totaled $97 million, representing a free cash flow yield of approximately 18% based on market capitalizations at the end of the quarter.
Capital Allocation Priority: In the near term, our capital allocation priority remains strengthening our balance sheet as we've committed to deleveraging in line with our stated capital allocation framework as we work towards our targeted leverage ratio of 3x.
Debt Repayment: We repaid $27 million of outstanding debt during the quarter and expect to repay approximately $100 million over the course of the fiscal year as we deliver sustained and attractive returns to shareholders over time.
The earnings call indicates positive sentiment with a focus on EBITDA growth, synergy realization, and operational efficiency. Product development highlights innovation and premium applications, particularly in South America. Despite some concerns in Europe, demand signals in North America are positive. The company targets significant debt reduction and free cash flow, with strong margins in innovative products. The Q&A section reinforces positive sentiment with stable competitive behavior and growth in adult incontinence. Overall, the outlook and strategic initiatives suggest a positive impact on stock price.
The earnings call shows mixed signals: strong growth in infection prevention wipes and operational efficiencies, but revenue declines in key segments. Positive aspects include EBITDA margin expansion and Project CORE's future benefits. However, cautious demand, unclear management responses, and regional challenges offset these. The Q&A highlights synergy realization and cautious optimism, but concerns about South America and Europe persist. The absence of a market cap limits prediction precision, but the balanced positives and negatives suggest a neutral stock price movement in the short term.
The earnings call presents a mixed outlook. Financial performance shows stable sales and EBITDA, but challenges in product mix and regional pressures persist. Q&A insights suggest ongoing efforts to address operational and competitive issues, yet uncertainties remain, particularly in South America and Europe. The company's guidance is cautious, with no major positive surprises or partnerships announced. High debt levels and capacity rationalization efforts further temper optimism. Overall, the sentiment is balanced, with no strong catalysts to drive significant stock price movement in either direction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.